Spotlight On... Valeant sets March 15 release for delayed Q4 results; Most doctors ready to prescribe biosims if discounts hit 25%; Market watchers piqued by Valeant CEO's one-on-ones with bullish analysts; and more...

Valeant ($VRX) investors eager for answers will get some on March 15, the company promised. That's when it now intends to release preliminary quarterly results--which it delayed last week for a variety of reasons, including pneumonia-stricken CEO J. Michael Pearson's comeback--and it'll hold a conference call that day, too. Release | More

@FiercePharma: Heska's topsy-turvy year ends on a high note as earnings beat estimates. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Victoza comes up big for Novo with key heart-risk lowering data. More | Follow @CarlyHFierce

> In some statistical evidence for common sense, a physician survey found that doctors would be most likely to prescribe biosimilar drugs at bigger discounts. Report

> Valeant ($VRX) CEO Michael Pearson's one-on-one calls with handpicked analysts last week raised eyebrows among other analysts and investors who are looking for more transparency at the embattled company. Report

> New Jersey's Alvogen has agreed to buy generic drugmaker County Line Pharmaceuticals. Release

> Accord Healthcare is bringing up to 100 new jobs to a Newcastle, U.K. site where Sanofi ($SNY) ceased operations last year. More

Medical Device News

@FierceMedDev: ICYMI: Siemens Healthcare CEO: restructured unit 'hungry' for M&A deals. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: AZ stokes $45B sales hopes with expanded approval for breast cancer drug Faslodex. More | Follow @EmilyWFierce

> FDA nod for smart contact lens that continuously monitors eye pressure changes in glaucoma. More

> Next up on Thermo Fisher's to-do list? Some serious M&A: Analyst. Report

> Senators butt heads over proposed device (and drug) industry regulatory overhaul. Article

Biotech News

@FierceBiotech: Celldex's cancer vaccine Rintega implodes in glioblastoma PhIII. News | Follow @FierceBiotech

@JohnCFierce: AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug. Report | Follow @JohnCFierce

> Bristol-Myers prints a pair of 'Golden Tickets' for Cambridge biotech startups. Report

> Europe takes a page from the FDA with new speedy approval program. Story

> Aimmune's peanut allergy drug clears Phase II on the way to a pivotal test. Article

Pharma Marketing News

> With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land. Report

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Item

> J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL. More

> DTC challenges mount as senators roll out bill to yank tax deduction. Story

> New privacy-friendly partnership taps consumer data to help pharma target mobile marketing. Article

Animal Health News

> Kindred projects increased spending as it preps for first commercial product. Item

> VCA adds 56 veterinary clinics by snapping up $344M stake in Las Vegas chain. Report

> Heska's topsy-turvy year ends on a high note as record earnings beat estimates. More

> Under pressure from activists, In-N-Out Burger jumps on antibiotic-free bandwagon. Story

> Zoetis launches first genomic test for predicting common diseases in Holsteins. Article

Biotech IT News

> Bristol-Myers signs deal to use Veeva tools for regulatory information. News

> U.K. firms team up to develop mental health-tracking wearable devices. Report

> GSK extends business process analytics contract to 2020. Story

> George Church's Veritas starts $999 whole-genome sequencing service. Item

> IPhone-based Parkinson's study shares 6 months of data on 9,500 participants. Article

And Finally... A study has identified a link between an ADHD med and diminished bone health in kids. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.